SYRE
$43.95
Spyre Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing therapeutics for patients living with inflammatory bowel disease (IBD) and rheumatic diseases.
Historical Price
Peer Comparison
Whystock Valuation Model
Fundamentals
Spyre Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing therapeutics for patients living with inflammatory bowel disease (IBD) and rheumatic diseases. The company develops SPY001, a humanized monoclonal immunoglobulin ...
Recent News
VR Adviser Adds Over 1 Million Savara Shares
This clinical-stage biotech develops inhaled therapies for rare respiratory diseases, with its lead candidate in Phase III trials.
Assessing Spyre Therapeutics (SYRE) Valuation After A Year Of Strong Shareholder Returns
Why Spyre Therapeutics Stock Is On Investors’ Radar Spyre Therapeutics (SYRE) has attracted attention after a strong share price move over the past year, alongside meaningful swings in shorter term returns that may prompt investors to reassess risk and reward. See our latest analysis for Spyre Therapeutics. Recent trading has been choppy, with a 2.32% 1 day share price return and a 6.56% 7 day share price decline. However, a 25.19% 30 day share price return and a 110.58% 1 year total...
From Sizable Stake to Zero: The Likely Reason Why Agios Shares Lost a $94 Million Backer
Agios Pharmaceuticals develops therapies for rare blood disorders, anchored by its PYRUKYND franchise and early-stage clinical programs.
Viridian Therapeutics Stock Up 75%, but One Fund Just Sold Off Its $69 Million Stake
Viridian Therapeutics develops monoclonal antibody therapies targeting rare diseases, with a focus on thyroid eye disease treatments.
Spyre Therapeutics Stock Surges This Past Year as $10.5 Million Buy Lifts Stake to $78 Million
Spyre Therapeutics develops preclinical monoclonal antibody therapies targeting inflammatory bowel disease and related conditions.